BACKGROUND: The standard treatment of osteosarcoma includes cisplatin and high-dose methotrexate (HDMTX); both agents exert significant toxicity, and HDMTX requires complex pharmacokinetic monitoring and leucovorin rescue. In the previous OS91 trial, the treatment of localized disease with carboplatin, ifosfamide, doxorubicin, and HDMTX yielded outcomes comparable to those of cisplatin-based regimens and caused less toxicity. To build on this experience, the authors conducted a multi-institutional trial (OS99) that evaluated the efficacy of carboplatin, ifosfamide, and doxorubicin without HDMTX in patients with newly diagnosed, localized, resectable osteosarcoma. METHODS: Treatment was comprised of 12 cycles of chemotherapy administered over 35 weeks: 3 cycles of carboplatin (dose targeted to area under the concentration-time curve of 8 mg/mL × min on Day 1) and ifosfamide (at a dose of 2.65 g/m(2) daily ×3 days) and 1 cycle of doxorubicin (at a dose of 25 mg/m(2) daily ×3 days) before surgical resection, followed by 2 additional cycles of the combination of carboplatin and ifosfamide and 3 cycles each of doxorubicin (25 mg/m(2) daily ×2 days) combined with ifosfamide or carboplatin. RESULTS: A total of 72 eligible patients (median age, 13.4 years) were enrolled between May 1999 and May 2006. Forty of the 66 (60.6%) evaluable patients had good histologic responses (>90% tumor necrosis) to preoperative chemotherapy. The estimated 5-year event-free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial (P = .98). The estimated 5-year survival rate was 78.9% ± 6.3% for the OS99 trial and 74.5% ± 6.3% for the OS91 trial (P = .40). CONCLUSIONS: The regimen used in the OS99 trial was found to produce outcomes comparable to those of cisplatin-containing or HDMTX-containing regimens. This therapy offers a good alternative for patients, particularly those who demonstrate an intolerance of HDMTX, and for institutions that cannot provide pharmacokinetic monitoring for MTX.
BACKGROUND: The standard treatment of osteosarcoma includes cisplatin and high-dose methotrexate (HDMTX); both agents exert significant toxicity, and HDMTX requires complex pharmacokinetic monitoring and leucovorin rescue. In the previous OS91 trial, the treatment of localized disease with carboplatin, ifosfamide, doxorubicin, and HDMTX yielded outcomes comparable to those of cisplatin-based regimens and caused less toxicity. To build on this experience, the authors conducted a multi-institutional trial (OS99) that evaluated the efficacy of carboplatin, ifosfamide, and doxorubicin without HDMTX in patients with newly diagnosed, localized, resectable osteosarcoma. METHODS: Treatment was comprised of 12 cycles of chemotherapy administered over 35 weeks: 3 cycles of carboplatin (dose targeted to area under the concentration-time curve of 8 mg/mL × min on Day 1) and ifosfamide (at a dose of 2.65 g/m(2) daily ×3 days) and 1 cycle of doxorubicin (at a dose of 25 mg/m(2) daily ×3 days) before surgical resection, followed by 2 additional cycles of the combination of carboplatin and ifosfamide and 3 cycles each of doxorubicin (25 mg/m(2) daily ×2 days) combined with ifosfamide or carboplatin. RESULTS: A total of 72 eligible patients (median age, 13.4 years) were enrolled between May 1999 and May 2006. Forty of the 66 (60.6%) evaluable patients had good histologic responses (>90% tumor necrosis) to preoperative chemotherapy. The estimated 5-year event-free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial (P = .98). The estimated 5-year survival rate was 78.9% ± 6.3% for the OS99 trial and 74.5% ± 6.3% for the OS91 trial (P = .40). CONCLUSIONS: The regimen used in the OS99 trial was found to produce outcomes comparable to those of cisplatin-containing or HDMTX-containing regimens. This therapy offers a good alternative for patients, particularly those who demonstrate an intolerance of HDMTX, and for institutions that cannot provide pharmacokinetic monitoring for MTX.
Authors: R L Souhami; A W Craft; J W Van der Eijken; M Nooij; D Spooner; V H Bramwell; R Wierzbicki; A J Malcolm; A Kirkpatrick; B M Uscinska; M Van Glabbeke; D Machin Journal: Lancet Date: 1997-09-27 Impact factor: 79.321
Authors: Paul A Meyers; Cindy L Schwartz; Mark Krailo; Eugenie S Kleinerman; Donna Betcher; Mark L Bernstein; Ernest Conrad; William Ferguson; Mark Gebhardt; Allen M Goorin; Michael B Harris; John Healey; Andrew Huvos; Michael Link; Joseph Montebello; Helen Nadel; Michael Nieder; Judith Sato; Gene Siegal; Michael Weiner; Robert Wells; Lester Wold; Richard Womer; Holcombe Grier Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544
Authors: Najat C Daw; Catherine A Billups; Carlos Rodriguez-Galindo; M Beth McCarville; Bhaskar N Rao; Alvida M Cain; Jesse J Jenkins; Michael D Neel; William H Meyer Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: A J Provisor; L J Ettinger; J B Nachman; M D Krailo; J T Makley; E J Yunis; A G Huvos; D L Betcher; E S Baum; C T Kisker; J S Miser Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: N Fuchs; S S Bielack; D Epler; P Bieling; G Delling; D Körholz; N Graf; U Heise; H Jürgens; R Kotz; M Salzer-Kuntschik; P Weinel; M Werner; K Winkler Journal: Ann Oncol Date: 1998-08 Impact factor: 32.976
Authors: N M Marina; J Rodman; S J Shema; L C Bowman; E Douglass; W Furman; V M Santana; M Hudson; J Wilimas; W Meyer Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Fariba Navid; Victor M Santana; Michael Neel; M Beth McCarville; Barry L Shulkin; Jianrong Wu; Catherine A Billups; Shenghua Mao; Vinay M Daryani; Clinton F Stewart; Michelle Kunkel; Wendene Smith; Deborah Ward; Alberto S Pappo; Armita Bahrami; David M Loeb; Jennifer Reikes Willert; Bhaskar N Rao; Najat C Daw Journal: Int J Cancer Date: 2017-07-03 Impact factor: 7.396
Authors: Lindsay Haynes; Sue C Kaste; Kirsten K Ness; Jianrong Wu; Lucia Ortega-Laureano; Michael Bishop; Michael Neel; Bhaskar Rao; Israel Fernandez-Pineda Journal: Pediatr Blood Cancer Date: 2016-11-05 Impact factor: 3.167
Authors: Junyu Guo; Wilburn E Reddick; John O Glass; Qing Ji; Catherine A Billups; Jianrong Wu; Fredric A Hoffer; Sue C Kaste; Jesse J Jenkins; Ximena C Ortega Flores; Juan Quintana; Milena Villarroel; Najat C Daw Journal: Cancer Date: 2011-12-16 Impact factor: 6.860
Authors: Israel Fernandez-Pineda; Najat C Daw; Beth McCarville; Liza J Emanus; Bhaskar N Rao; Andrew M Davidoff; Stephen J Shochat Journal: J Pediatr Surg Date: 2012-06 Impact factor: 2.545
Authors: Amos H P Loh; Huiyun Wu; Armita Bahrami; Fariba Navid; M Beth McCarville; Chong Wang; Jianrong Wu; Michael W Bishop; Najat C Daw; Michael D Neel; Bhaskar N Rao Journal: Pediatr Blood Cancer Date: 2014-11-08 Impact factor: 3.167
Authors: Amos H P Loh; Fariba Navid; Chong Wang; Armita Bahrami; Jianrong Wu; Michael D Neel; Bhaskar N Rao Journal: Ann Surg Oncol Date: 2014-02-21 Impact factor: 5.344